When does palivizumab’s patent expire?
I can’t give a single “the” expiry date from the information provided, because patent expiry for palivizumab depends on which specific patent(s) and which country’s filing you mean. [1]
What patents cover palivizumab, and why the date varies?
Palivizumab is covered by multiple patent families (covering aspects like manufacturing, formulations, and use), and those patents expire on different schedules depending on filing dates and local patent law in each jurisdiction. [1]
How do “patent expiry” and “exclusivity” differ for palivizumab?
Even after a patent expires, regulatory exclusivity or other protections (such as additional patents filed around the product) can delay market entry of competitors. So “patent expiry” and “when a biosimilar can launch” are not always the same date. [1]
Where can biosimilars enter after patent expiry?
A biosimilar’s ability to market depends on the status of relevant patents and regulatory exclusivities in the country where approval is sought. Without a specific patent list and jurisdiction, the earliest possible entry date can’t be determined. [1]
What I need to give you an exact expiry date
Share at least one of the following, and I’ll map it to the likely expiry window:
- The country/region (US, EU, UK, etc.)
- Whether you mean the original brand (Synagis) or a specific jurisdiction’s approved product label
- Any patent number(s) you’ve seen referenced, or a link to the patent record
Sources:
1. https://www.google.com/search?q=palivizumab+patent+expiry